PepGen Inc.
PEPG•NASDAQ•Healthcare•Biotechnology

About PepGen

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOJames McArthur
Founded2018
IPO DateMay 6, 2022
Employees81
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitepepgen.com
Phone781 797 0979
Address
321 Harrison Avenue, 8th Floor Boston, Massachusetts 02118 United States

Corporate Identifiers

CIK0001835597
CUSIP713317105
ISINUS7133171055
SIC2834

Leadership Team & Key Executives

Dr. James G. McArthur Ph.D.
President, Chief Executive Officer, Treasurer, Secretary and Director
Noel P. Donnelly M.B.A.
Chief Financial Officer
Dr. Paul D. Streck M.B.A., M.D.
Executive Vice President and Head of Research and Development
Dr. Michael Gait Ph.D.
Founder and Scientific Advisory Board Member
Dr. Kasra Kasraian Ph.D.
Chief Technology Officer
Emiko Bryant
Senior Vice President of Human Resources and Administration
Joseph D. Vittiglio Esq., J.D.
Chief Business and Legal Officer
Dr. Hayley Parker Ph.D.
Senior Vice President of Global Regulatory Affairs
Dr. Afsaneh Mohebbi Ph.D.
Senior Vice President of Portfolio and Program Management